Albumin-interleukin-2

Drug Profile

Albumin-interleukin-2

Alternative Names: Albuleukin; Albumin-interleukin-2 fusion protein

Latest Information Update: 25 May 2005

Price : $50

At a glance

  • Originator Human Genome Sciences
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 25 May 2005 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 20 Jul 2004 This compound is still in active development
  • 03 Dec 2003 Data presented at the 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc-2003) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top